<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01038661</url>
  </required_header>
  <id_info>
    <org_study_id>DOCET_L_04827</org_study_id>
    <nct_id>NCT01038661</nct_id>
  </id_info>
  <brief_title>Tax First-line Chemotherapy With Different Doses and Then Maintenance Therapy</brief_title>
  <acronym>TFINE</acronym>
  <official_title>Randomized, Controlled Study Comparing the Efficacy and Safety of Docetaxel （60mg/m2）Maintenance Treatment vs. Best Supportive Care Following First Line Chemotherapy With Different Doses of Docetaxel（75/60mg/m2）in Combination With Cisplatin in Patients With Local Advanced or Metastatic （Stage IIIB/IV）Non-Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Primary Objective is to evaluate the progression-free survival (PFS).&#xD;
&#xD;
      The secondary objectives are:&#xD;
&#xD;
        -  To compare the disease control rates of different doses of Docetaxel+Cisplatin as&#xD;
           first-line treatment according to Response Evaluation Criteria In Solid Tumors (RECIST)&#xD;
           criteria;&#xD;
&#xD;
        -  To evaluate the overall response rate (ORR);&#xD;
&#xD;
        -  To evaluate the time to disease progression (TTP);&#xD;
&#xD;
        -  To evaluate the overall survival (OS);&#xD;
&#xD;
        -  To evaluate the toxicity.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study consists in:&#xD;
&#xD;
        -  A first line treatment phase: participants receive 4 cycles of chemotherapy (each cycle&#xD;
           contains 3 weeks) with either docetaxel (75 mg/m2) plus cisplatin (75 mg/m2) or&#xD;
           docetaxel (60 mg/m2) plus cisplatin (75 mg/m2) ,&#xD;
&#xD;
        -  A maintenance treatment phase: participants with disease control (complete response&#xD;
           [CR], partial response [PR] or stable disease [SD]) after the initial treatment receive&#xD;
           up to 6 cycles of chemotherapy with docetaxel (60 mg/m2) or best supportive care (BSC).&#xD;
&#xD;
        -  A follow-up period from the end of study treatment until participant death or end of&#xD;
           study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2009</start_date>
  <completion_date type="Actual">August 2012</completion_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival (PFS) during the maintenance treatment phase</measure>
    <time_frame>From 2nd randomization to progression or death of any cause (every 2 cycles (6 weeks) during study treatment, and then every 8 weeks during follow-up period)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR) during the first line treatment phase</measure>
    <time_frame>Every 2 cycles (6 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response rate (ORR) during the first line treatment phase</measure>
    <time_frame>Every 2 cycles (6 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to disease progression (TTP) during the maintenance treatment phase</measure>
    <time_frame>From 2nd randomization up to disease progression (every 2 cycles (6 weeks))</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>From 1st randomization to death of any cause (every 2 cycles (6 weeks) during study treatment, and then every 8 weeks during follow-up period)</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">375</enrollment>
  <condition>Lung Neoplasms</condition>
  <arm_group>
    <arm_group_label>First line treatment: docetaxel 75 mg/m² + cisplatin 75 mg/m²</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Docetaxel 75 mg/m² + cisplatin 75 mg/m² on day 1, repeated every 3 weeks, up to 4 cycles</description>
  </arm_group>
  <arm_group>
    <arm_group_label>First line treatment:: docetaxel 60 mg/m² + cisplatin 75 mg/m²</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Docetaxel 60 mg/m² + cisplatin 75 mg/m² on day 1, repeated every 3 weeks, up to 4 cycles</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Maintenance treatment: docetaxel (60 mg/m2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Docetaxel 60 mg/m² on day 1, repeated every 3 weeks until progressive disease or up to 6 cycles</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Maintenance treatment: best supportive care (BSC)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>BSC until progressive disease</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>Formulation: concentrated solution for intravenous infusion (IV)&#xD;
Route(s) of administration: 1-hour IV</description>
    <arm_group_label>First line treatment: docetaxel 75 mg/m² + cisplatin 75 mg/m²</arm_group_label>
    <arm_group_label>First line treatment:: docetaxel 60 mg/m² + cisplatin 75 mg/m²</arm_group_label>
    <arm_group_label>Maintenance treatment: docetaxel (60 mg/m2)</arm_group_label>
    <other_name>Taxotere®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Formulation: concentrated solution for intravenous infusion (IV)&#xD;
Route(s) of administration: 1-3-hour IV</description>
    <arm_group_label>First line treatment: docetaxel 75 mg/m² + cisplatin 75 mg/m²</arm_group_label>
    <arm_group_label>First line treatment:: docetaxel 60 mg/m² + cisplatin 75 mg/m²</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Best supportive care (BSC)</intervention_name>
    <description>Any treatment including palliative radiotherapy for pain relief-but not chemotherapy - that is considered appropriate by the investigator</description>
    <arm_group_label>Maintenance treatment: best supportive care (BSC)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Histologic or cytologic diagnosis of advanced non-small-cell lung cancer (NSCLC)&#xD;
&#xD;
          -  Based on International Association for the Study of Lung Cancer (IASLC) 2009 new&#xD;
             Tumor-Node-Metastasis (TNM) stage criteria of lung cancer, local advanced stage IIIB&#xD;
             (not applicable for radical radiation therapy) disease or metastatic stage IV disease&#xD;
             or recurrent disease&#xD;
&#xD;
          -  At least one evaluable tumor lesion based on RECIST criteria (&gt;= 20 mm with&#xD;
             conventional techniques or &gt;= 10 mm with spiral Computed Tomography scan)&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group performance status (ECOG PS) 0/1&#xD;
&#xD;
          -  Adequate bone marrow reserve&#xD;
&#xD;
               -  absolute neutrophil count &gt;= 2.0×10^9/L&#xD;
&#xD;
               -  platelets &gt;= 100×10^9/L&#xD;
&#xD;
               -  hemoglobin &gt;= 9.0 g/dL&#xD;
&#xD;
          -  Adequate hepatic function&#xD;
&#xD;
               -  total bilirubin &lt;= Upper Normal Limit (UNL)&#xD;
&#xD;
               -  Aspartate Amino Transferase (AST), Alanine Amino Transferase (ALT) &lt;= 2.5 UNL&#xD;
&#xD;
               -  alkaline phosphatase (ALP) &lt;= 5 UNL&#xD;
&#xD;
          -  Adequate renal function (serum creatinine &lt;= UNL or creatinine clearance &gt;= 60 mL/min)&#xD;
&#xD;
          -  No prior chemotherapy was allowed or only (neo) adjuvant chemotherapy ended more than&#xD;
             6 months before treatment (patients should not have been heavily pre-treated, the&#xD;
             maximum cumulative dose of cisplatin allowed is 350 mg/m²)&#xD;
&#xD;
          -  Prior surgery was permitted only if the operation performed more than 4 weeks ago and&#xD;
             the patient was completely recovery&#xD;
&#xD;
          -  Childbearing potential either terminated or attenuated by the use of an approved&#xD;
             contraceptive method&#xD;
&#xD;
          -  Inform consent signed&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Other tumour type than advanced / metastatic NSCLC in recent 5 years (except&#xD;
             cone-biopsied carcinoma-in-situ of the cervix or adequately treated basal or squamous&#xD;
             cell carcinoma of the skin).&#xD;
&#xD;
          -  Presence of symptomatic central nervous system metastases&#xD;
&#xD;
          -  Inadequate liver function&#xD;
&#xD;
               -  total bilirubin &gt; 1 UNL&#xD;
&#xD;
               -  ALT and/or AST&gt;1.5 UNL associated with alkaline phosphatase &gt; 2.5 UNL&#xD;
&#xD;
               -  inadequate renal function (creatinine &gt; 1.0 times UNL and in case of limit value,&#xD;
                  creatinine clearance &lt; 60 mL/min)&#xD;
&#xD;
          -  Prior radiation therapy, or surgery operation within 4 weeks&#xD;
&#xD;
          -  Prior use of taxoids&#xD;
&#xD;
          -  Active infection, or serious concomitant systemic disorder incompatible with the study&#xD;
&#xD;
          -  Childbearing potential but unwilling to use of an approved contraceptive method&#xD;
&#xD;
          -  Receive treatment from other clinical trials during this study treatment&#xD;
&#xD;
          -  History of hypersensitivity to any of study medication&#xD;
&#xD;
          -  Other serious concomitant abnormal or illness&#xD;
&#xD;
        The above information is not intended to contain all considerations relevant to a patient's&#xD;
        potential participation in a clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <study_first_submitted>December 22, 2009</study_first_submitted>
  <study_first_submitted_qc>December 22, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 24, 2009</study_first_posted>
  <last_update_submitted>February 27, 2014</last_update_submitted>
  <last_update_submitted_qc>February 27, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 28, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

